Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial

Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial

Abstract Background HER2 dual-blockade combined with aromatase inhibitors (AI) is a promising strategy to improve progression-free survival (PFS) in hormone receptor (HR) positive, metastatic breast cancer (MBC). Pyrotinib is a novel irreversible epidermal growth factor receptor/HER2 dual tyrosine k...

Full description

Bibliographic Details
Main Authors: Changjun Wang, Yan Lin, Yidong Zhou, Feng Mao, Hanjiang Zhu, Jinghong Guan, Xiaohui Zhang, Songjie Shen, Xin Huang, Chang Chen, Ru Yao, Jialin Zhao, Qiang Sun
Format: Article
Language:English
Published: BMC 2020-07-01
Series:BMC Cancer
Subjects:
Metastatic breast cancer
Pyrotinib
Aromatase inhibitors
Trastuzumab
Online Access:http://link.springer.com/article/10.1186/s12885-020-07143-2

Internet

http://link.springer.com/article/10.1186/s12885-020-07143-2

Similar Items